No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | 533 | 681 | 1,142 | 1,396 | 1,536 | 1,983 | 2,355 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | 8 | 37 | 74 | 104 | 146 | 267 | 302 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for export. Their extensive portfolio includes a broad spectrum of parenteral and nasal formulations, addressing various therapeutic categories such as gastroenterology, anti-inflammatory conditions, epilepsy, malaria, and infections, among others. These are available in diverse formats like ampoules, vials, and dry powder injectables, and feature specialized offerings like iron supplements, metered nasal drops, and proprietary brands such as Klavmox and Onecef. The company also manufactures a variety of oral medications, including tablets, capsules, dry syrups, gripe water, and oral liquids and powders, targeting areas such as antibiotics, anti-diabetics, and cardiovascular health. Beyond traditional pharmaceuticals, Kilitch offers effervescent tablets and powders, exemplified by products like ROIPAR, DUREGRA, ROIVIT, and PH-7, as well as nutritional products such as CELTINE. Their innovative solutions include C-Seal, a topical skin adhesive designed for closing wounds without sutures. Furthermore, their product range extends to cosmetics and herbal remedies, encompassing various oils, lotions, liquids, creams, and pastes for skin, personal, and hair care, alongside herbal supplements for conditions like sore throat, prostate issues, diabetes, obesity, and libido enhancement.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kilitch Drugs (India) Limited (KILITCH.NS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for export. Their extensive portfolio includes a broad spectrum of parenteral and nasal formulations, addressing various therapeutic categories such as gastroenterology, anti-inflammatory conditions, epilepsy, malaria, and infections, among others. These are available in diverse formats like ampoules, vials, and dry powder injectables, and feature specialized offerings like iron supplements, metered nasal drops, and proprietary brands such as Klavmox and Onecef. The company also manufactures a variety of oral medications, including tablets, capsules, dry syrups, gripe water, and oral liquids and powders, targeting areas such as antibiotics, anti-diabetics, and cardiovascular health. Beyond traditional pharmaceuticals, Kilitch offers effervescent tablets and powders, exemplified by products like ROIPAR, DUREGRA, ROIVIT, and PH-7, as well as nutritional products such as CELTINE. Their innovative solutions include C-Seal, a topical skin adhesive designed for closing wounds without sutures. Furthermore, their product range extends to cosmetics and herbal remedies, encompassing various oils, lotions, liquids, creams, and pastes for skin, personal, and hair care, alongside herbal supplements for conditions like sore throat, prostate issues, diabetes, obesity, and libido enhancement.
